Using genetic and immune markers to improve lung cancer treatment before surgery
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer
This study is looking at how certain genetic and immune features of non-small cell lung cancer can help doctors figure out if immunotherapy before surgery will work well for patients, so they can create more personalized treatment plans.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10916553 on NIH RePORTER |
What this research studies
This research investigates how specific genetic and immune characteristics of non-small cell lung cancer (NSCLC) can predict the effectiveness of immunotherapy treatments given before surgery. By analyzing tumor samples and patient data, the study aims to identify biomarkers that can help tailor treatment plans for better outcomes. The approach includes using advanced imaging techniques and computational tools to assess the tumor's response to neoadjuvant immunotherapy. Patients will be monitored for changes in their tumors and immune responses throughout the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with resectable non-small cell lung cancer who are eligible for neoadjuvant immunotherapy.
Not a fit: Patients with advanced or metastatic lung cancer that is not operable may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for patients with non-small cell lung cancer, potentially improving survival rates.
How similar studies have performed: Previous studies have shown promising results with neoadjuvant immunotherapy in lung cancer, indicating that this approach could be effective.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Wu, Jia — University of Tx Md Anderson Can Ctr
- Study coordinator: Wu, Jia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.